Sevuparin for severe malaria: process & method development
| Reference number | |
| Coordinator | DILAFORETTE AB - DILAFORETTE AB, Solna |
| Funding from Vinnova | SEK 2 850 000 |
| Project duration | November 2012 - May 2014 |
| Status | Completed |
Purpose and goal
Dilaforette aims to develop sevuparin, a new drug to treat vaso-occlusion in severe malaria, sickle cell anemia and other indications. The project was aimed to develop an improved method of manufacturing sevuparin in a larger scale suitable for commercial production, as well as improve the quality and simplify the realease methods.
Results and expected effects
Dilaforette have now developed a new process, scaled up to commercial scale and moved production to a new manufacturer that can meet the requirements as final drug producer. There are just over 6 kg drug substance in stock. The goal of the project has been met. The results allow for Dilaforette to move forward in the development of the drug. It also increases the company´s ability to eventually commercialize the new drug, both by reducing manufacturing costs and improving quality.
Approach and implementation
Dilaforettes planned to recruit 1-2 people for the projectmanaging of the process and methodology development. However, the company managed instead by part-time employment of one of the founders, with unique process expertise, as well as bringing in an consultant for the overall process development coordination.